Answers are grounded in this paper and cite their sources.
T cell non-Hodgkin lymphomas (TNHL) are an uncommon and heterogeneous group of lymphoid malignancies characterized by a poor prognosis. They usually present with advanced-stage disease and high International Prognostic Index (IPI) score [1]. Patients with TNHL treated with conventional-dose chemotherapy alone in general have inferior overall survival (OS) and event-free survival compared to those with diffuse large B cell lymphoma [2]. High-dose therapy and autologous hematopoietic stem cell transplantation (HSCT) in relapsed or refractory patients have produced 3-yr OS and progression free survival (PFS) rates of 35%-58% and 28%-50% respectively [1,3-5].
No takes yet. Share an insight, caveat, or question.
Hamadani et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: